PDCD1 and colorectal carcinoma: Furthermore, OS was higher after PD-1 inhibitor plus apatinib treatment than after apatinib monotherapy in patients with a single metastatic site, thus indicating that CRC patients with a single metastatic site could achieve greater benefit after PD-1 inhibitor plus apatinib treatment.